Systemic Lupus Erythematosus

Rheumatology

Clinicals - History

Fact Explanation
Introduction Systemic Lupus Erythematosus is an autoimmune connective tissue disorder. This is the commonest connective tissue disorder which affects multi-systems. Majority (90%) of patients are women in child bearing ages But this can affect both sexes in all ages. the prevalence is around 15-50: 100 000.
In this condition Various antigentc stimulation causes wide spectrum of antibody production following B and T cell activation. The exact triggering factors for autoantibody production is unknown. Following this abnormal immune response. Antibodies or antigen-antibody complexes deposition in various organs causes influx of neutrophils and lymphocytes inducing inflammatory reaction. Ongoing same reactions finally leads to permanent organ damage.
Introduction
Systemic Lupus Erythematosus is an autoimmune connective tissue disorder. This is the commonest connective tissue disorder which affects multi-systems. Majority (90%) of patients are women in child bearing ages But this can affect both sexes in all ages. the prevalence is around 15-50: 100 000.
In this condition Various antigentc stimulation causes wide spectrum of antibody production following B and T cell activation. The exact triggering factors for autoantibody production is unknown. Following this abnormal immune response. Antibodies or antigen-antibody complexes deposition in various organs causes influx of neutrophils and lymphocytes inducing inflammatory reaction. Ongoing same reactions finally leads to permanent organ damage.
Fever, weight loss and other constitutional symptoms like malaise, lethargy, fatiguability These symptoms are common during exacerbation due to increased metabolic activity. But these features are not related to the severity of disease activity or complications. Fever, weight loss and other constitutional symptoms like malaise, lethargy, fatiguability
These symptoms are common during exacerbation due to increased metabolic activity. But these features are not related to the severity of disease activity or complications.
Joint pain Joint involvement is the main complain and this can be seen in more then 90% of patients. patient will complain of bilateral symmetrical small joint pain with mild morning stiffness. It can be a migratory arthralgia. Some times there will be swelling as well.
Rarely there will be pain in major joints. these patients are at risk of developing aseptic necrosis of the hip/ knee as a rare
complication of the disease or following the treatment with
corticosteroids.
Joint pain
Joint involvement is the main complain and this can be seen in more then 90% of patients. patient will complain of bilateral symmetrical small joint pain with mild morning stiffness. It can be a migratory arthralgia. Some times there will be swelling as well.
Rarely there will be pain in major joints. these patients are at risk of developing aseptic necrosis of the hip/ knee as a rare
complication of the disease or following the treatment with
corticosteroids.
development of severe pain and bluish discoloration over tip of fingers after exposure to cool water. This called Raynaud’s phenomenon. These symptoms occur following vasculitis. These symptoms commonly associated with arthralgia or arthritis. development of severe pain and bluish discoloration over tip of fingers after exposure to cool water.
This called Raynaud’s phenomenon. These symptoms occur following vasculitis. These symptoms commonly associated with arthralgia or arthritis.
Muscle pain and weakness around 50% of patients can develop myalgia but only few patients develop myositis. Muscle pain and weakness
around 50% of patients can develop myalgia but only few patients develop myositis.
Skin rash ( may be painful/ pruritic) eruthematous rash on the cheeks aross the nasal bridge (butterfly rash).
purpura and urticarial rash over the tip of the fingers and nail folds. These are caused by vasculitis (vasculitic rash).
there will be other skin changes like Livedo reticularis and periungual erythema.
Patient may also develop palmar and plantar rashes.
Patients may develop a erythematous rash in face with well defined margins. there plques can ultimately lead to scarring and pigmentations (Discoid rash).
In Subacute cutaneous lupus erythematosus, there is a migratory, non-scarring, papulosquamous/ annular rash.
Skin rash ( may be painful/ pruritic)
eruthematous rash on the cheeks aross the nasal bridge (butterfly rash).
purpura and urticarial rash over the tip of the fingers and nail folds. These are caused by vasculitis (vasculitic rash).
there will be other skin changes like Livedo reticularis and periungual erythema.
Patient may also develop palmar and plantar rashes.
Patients may develop a erythematous rash in face with well defined margins. there plques can ultimately lead to scarring and pigmentations (Discoid rash).
In Subacute cutaneous lupus erythematosus, there is a migratory, non-scarring, papulosquamous/ annular rash.
alopecia Patients with disoid lupus, commonly developed scarred alopecia causing permanent skin loss (following discoid rash over the scalp). alopecia
Patients with disoid lupus, commonly developed scarred alopecia causing permanent skin loss (following discoid rash over the scalp).
generalized body swelling, reduced urine output, haematuria/ frothy urine. Patients with renal involvement can develop these features of renal impairment. Thought histological changes of glomerulonephritis are occur in majority of patients with SLE only few will presennt with clinical symptoms. generalized body swelling, reduced urine output, haematuria/ frothy urine.
Patients with renal involvement can develop these features of renal impairment. Thought histological changes of glomerulonephritis are occur in majority of patients with SLE only few will presennt with clinical symptoms.
Difficulty in breathing, pleuritic type chest pain, Patient will develop chest pain and difficulty in breathing following Pneumonitis, atelectasis. Patients also commonly develop bilateral exudative pleural effusions following pleuritis. With these lung manifestations there will reduction of lung volumes (shrinking lung syndrome). Rarely lung fibrosis can occur with Systemic Lupus Erythematosus. 50% people will have lung involvement. Intrapulmonary haemorrhages (due to vasculitis) can cause life threatening conditions. Difficulty in breathing, pleuritic type chest pain,
Patient will develop chest pain and difficulty in breathing following Pneumonitis, atelectasis. Patients also commonly develop bilateral exudative pleural effusions following pleuritis. With these lung manifestations there will reduction of lung volumes (shrinking lung syndrome). Rarely lung fibrosis can occur with Systemic Lupus Erythematosus. 50% people will have lung involvement. Intrapulmonary haemorrhages (due to vasculitis) can cause life threatening conditions.
chest pain, palpitation, dizziness cardiac involvement can be seen in 25% of cases. Pericarditis with pericardial effusion, myocaditis causing arrhythmias, valve lesions with cardiomyopathy, arterial and venous thrombosis following vasculitis can be seen. These patients are at risk of developing strokes and ischemic heart diseases. chest pain, palpitation, dizziness
cardiac involvement can be seen in 25% of cases. Pericarditis with pericardial effusion, myocaditis causing arrhythmias, valve lesions with cardiomyopathy, arterial and venous thrombosis following vasculitis can be seen. These patients are at risk of developing strokes and ischemic heart diseases.
features of hypoperfusion/ ischemia following vasculitis Due to the cardiac involvement and with the possibility of arterial and venous thrombus formation with vasculitis, patients are at risk of developing organ hypoperfusion.
Eg: Brain strokes can occur giving features of paralysis, paresthesia and cranial nerve palsy.
In spinal cord, features of infarction like limb paralysis, paresthesia, bladder/ bowel dysfunction.
In bones, ischemic pain at site of the joint/back pain and fractures following long bone infarction can be seen.
Myocardial infarctions can occur following hypoperfusion of the myocardium( chest pain, difficulty in breathing, dizziness).
In lungs there will be shortness of breath and pleuritic type chest pain.
In mesentry, acute abdominal pain will be the presentation.
In digits, painful fingers and toes with small bone infarction.
In kidneys infarction of medulla with papillary necrosis may lead to fail in concentrating urine causing high urine out put, dehydration and nocturnal enuresis.
Chronic liver failure with micro infarction causing loss of appetite, yellowish discoloration of eyes.
Splenic infarction leads to recurrent infections like upper/ lower respiratory tract infections and diarrheal illnessess.
features of hypoperfusion/ ischemia following vasculitis
Due to the cardiac involvement and with the possibility of arterial and venous thrombus formation with vasculitis, patients are at risk of developing organ hypoperfusion.
Eg: Brain strokes can occur giving features of paralysis, paresthesia and cranial nerve palsy.
In spinal cord, features of infarction like limb paralysis, paresthesia, bladder/ bowel dysfunction.
In bones, ischemic pain at site of the joint/back pain and fractures following long bone infarction can be seen.
Myocardial infarctions can occur following hypoperfusion of the myocardium( chest pain, difficulty in breathing, dizziness).
In lungs there will be shortness of breath and pleuritic type chest pain.
In mesentry, acute abdominal pain will be the presentation.
In digits, painful fingers and toes with small bone infarction.
In kidneys infarction of medulla with papillary necrosis may lead to fail in concentrating urine causing high urine out put, dehydration and nocturnal enuresis.
Chronic liver failure with micro infarction causing loss of appetite, yellowish discoloration of eyes.
Splenic infarction leads to recurrent infections like upper/ lower respiratory tract infections and diarrheal illnessess.
seizures, alteration in mental status, headache, poor concentration 60% of patient will develop cerebral lupus. theses patients are at risk of developing epilepsy, migraines, poor concentration, cerebellar ataxia, aseptic meningitis, cranial nerve lesions, cerebrovascular disease and polyneuropathy. Also there can be visual hallucinations, chorea, organic psychosis. seizures, alteration in mental status, headache, poor concentration
60% of patient will develop cerebral lupus. theses patients are at risk of developing epilepsy, migraines, poor concentration, cerebellar ataxia, aseptic meningitis, cranial nerve lesions, cerebrovascular disease and polyneuropathy. Also there can be visual hallucinations, chorea, organic psychosis.
eye pain, redness of the eyes and visual impairment With vasculitis there will be retinal infarctions leading to hard exudates, and haemorrhages. Also patients can develop episcleritis, conjunctivitis, optic neuritis and Sjögren’s syndrome (dry eyes and mucous menmbranes). Though several eye complications can occur, blindness is very rare. eye pain, redness of the eyes and visual impairment
With vasculitis there will be retinal infarctions leading to hard exudates, and haemorrhages. Also patients can develop episcleritis, conjunctivitis, optic neuritis and Sjögren’s syndrome (dry eyes and mucous menmbranes). Though several eye complications can occur, blindness is very rare.
yellowish discoloration of the eyes, oral ulcers, sudden onset abdominal pain patient with Systemic Lupus Erythematosus can develop oral ulcers, mesenteric ischemia (causes abdominal pain), bowel perforation (causes acute abdomen with sudden onset severe abdominal pain, and features of septicaemia), liver failure( right hypochondrial pain, icterus, loss of weight, loss of appetitie) and pancreatitis ( causing diabetes mellitus and features of food indigestion).
In an acute flareup patient can develop nausea, vomiting and diarrhoea.
yellowish discoloration of the eyes, oral ulcers, sudden onset abdominal pain
patient with Systemic Lupus Erythematosus can develop oral ulcers, mesenteric ischemia (causes abdominal pain), bowel perforation (causes acute abdomen with sudden onset severe abdominal pain, and features of septicaemia), liver failure( right hypochondrial pain, icterus, loss of weight, loss of appetitie) and pancreatitis ( causing diabetes mellitus and features of food indigestion).
In an acute flareup patient can develop nausea, vomiting and diarrhoea.
recurrent infections, easy fatiguabilty, increased bleeding tendency patients can develop neutropenia, lymphopenia, thrombocytopenia and haemolytic anaemia. recurrent infections, easy fatiguabilty, increased bleeding tendency
patients can develop neutropenia, lymphopenia, thrombocytopenia and haemolytic anaemia.
Past gynaecological history of recurrent miscarriages These patients are at risk of getting recurrent miscarriages. The exact mechanism is unknown. There is an increased frequency of an exacerbations during pregnancy and postpartum . Past gynaecological history of recurrent miscarriages
These patients are at risk of getting recurrent miscarriages. The exact mechanism is unknown. There is an increased frequency of an exacerbations during pregnancy and postpartum .
Obstetric history of exacerbations during pregnancy/ post partum period and History of exacerbations during pregnancy/ post partum period. History of giving birt to a baby with neonatal lupus syndrome. In here neonate will develop rash, hepatitis and heart block. Obstetric history of exacerbations during pregnancy/ post partum period and
History of exacerbations during pregnancy/ post partum period. History of giving birt to a baby with neonatal lupus syndrome. In here neonate will develop rash, hepatitis and heart block.
history of hormone replacement therapy Parimenopausal women in their child bearing ages are at risk of developing Systemic Lupus Erythematosus. Males with Klinefelter’s syndrome also at risk of developing this condition campare to normal males. Hormone replacement therapy is known to induce flareups. history of hormone replacement therapy
Parimenopausal women in their child bearing ages are at risk of developing Systemic Lupus Erythematosus. Males with Klinefelter’s syndrome also at risk of developing this condition campare to normal males. Hormone replacement therapy is known to induce flareups.
Drug history Some drugs like hydralazine, isoniazid, procainamide, penicillamine can induce this condition. Drug history
Some drugs like hydralazine, isoniazid, procainamide, penicillamine can induce this condition.
History of exposure to sun light Ultraviolet light is a known triggering factor. History of exposure to sun light
Ultraviolet light is a known triggering factor.
History of recent Epstein–Barr virus infection Exposure to Epstein–Barr virus also a known predisposing factor. History of recent Epstein–Barr virus infection
Exposure to Epstein–Barr virus also a known predisposing factor.
Family history of diagnosed SLE or feature suggestive of SLE Systemic Lupus Erythematosus goes as a hereditory disease. Deficiencies of the complement
genes C1q, C2 or C4 are at risk of developing Systemic Lupus Erythematosus.
Family history of diagnosed SLE or feature suggestive of SLE
Systemic Lupus Erythematosus goes as a hereditory disease. Deficiencies of the complement
genes C1q, C2 or C4 are at risk of developing Systemic Lupus Erythematosus.
Past medical history In a diagnosed patient complete past medical history will be useful in further management. About previous episodes, complications, tratments given, medications which patient is currently on. Past medical history
In a diagnosed patient complete past medical history will be useful in further management. About previous episodes, complications, tratments given, medications which patient is currently on.

Clinicals - Examination

Fact Explanation
General examination- febrile, ill looking patient with mild lumphadenopathy and evidence of loss of weight. These symptoms are common during exacerbations due to increased metabolic activity. General examination- febrile, ill looking patient with mild lumphadenopathy and evidence of loss of weight.
These symptoms are common during exacerbations due to increased metabolic activity.
Joint examination characteristically joints are normal despite of pain. Mildly swollen, tender small joints can be identified. These symptoms are usually symmetrical.
Rarely joint deformities can be seen due to bony erosions (Jaccoud's arthropathy) and contractions of the joint capsule and tendon following long term inflammatory process. Major joints also can involved.
Joint examination
characteristically joints are normal despite of pain. Mildly swollen, tender small joints can be identified. These symptoms are usually symmetrical.
Rarely joint deformities can be seen due to bony erosions (Jaccoud's arthropathy) and contractions of the joint capsule and tendon following long term inflammatory process. Major joints also can involved.
capillary nail-fold loops examination and observation of Raynaud’s phenomenon This can be done with an ophthalmoscope. It is helpful in distinguishing primary from secondary Raynaud's (loss of the normal loop pattern and capillary 'fallout' with haemorrhage and dots indicate underlying disease).
Raynaud’s phenomenon can be observed while patient handling the cool water.
capillary nail-fold loops examination and observation of Raynaud’s phenomenon
This can be done with an ophthalmoscope. It is helpful in distinguishing primary from secondary Raynaud's (loss of the normal loop pattern and capillary 'fallout' with haemorrhage and dots indicate underlying disease).
Raynaud’s phenomenon can be observed while patient handling the cool water.
Muscle examination If the patient is having myositis there will be tenderness on examination. Muscle examination
If the patient is having myositis there will be tenderness on examination.
examination of the skin On examination there will be various types of rashes.
eg: eruthematous rash on the cheeks aross the nasal bridge (butterfly rash).
Purpura and urticarial rash over the tip of the fingers and nail folds.
Skin changes like Livedo reticularis and periungual erythema.
Erythematous rash in face with well defined margins. With time these plques may lead to scarring and pigmentations (Discoid rash).
In Subacute cutaneous lupus erythematosus, there will be a migratory, non-scarring, papulosquamous/ annular rash.
examination of the skin
On examination there will be various types of rashes.
eg: eruthematous rash on the cheeks aross the nasal bridge (butterfly rash).
Purpura and urticarial rash over the tip of the fingers and nail folds.
Skin changes like Livedo reticularis and periungual erythema.
Erythematous rash in face with well defined margins. With time these plques may lead to scarring and pigmentations (Discoid rash).
In Subacute cutaneous lupus erythematosus, there will be a migratory, non-scarring, papulosquamous/ annular rash.
scalp examination This will reveals alopacia. It can be either scarring or non scarring alopacia. scalp examination
This will reveals alopacia. It can be either scarring or non scarring alopacia.
look for features of renal impairment and examine urine in presence of haematuria/ proteinuria. Generalized body swelling, pallor, haematuria will suggest the renal involvement. look for features of renal impairment and examine urine in presence of haematuria/ proteinuria.
Generalized body swelling, pallor, haematuria will suggest the renal involvement.
Respiratory system examination This will reveals the signs of bilateral pleural effusion( reduced lung expansion, stony dullness on percussion), signs of fibrosis (reduced air entry, presence of brochial breathing, dullness on percussion, increased vocal resonance). Respiratory system examination
This will reveals the signs of bilateral pleural effusion( reduced lung expansion, stony dullness on percussion), signs of fibrosis (reduced air entry, presence of brochial breathing, dullness on percussion, increased vocal resonance).
Central nervous System examination On examination there will be seizures, cerebral ataxia, features of meningits (headache, photophobia, neck stiffness), cranial nerve palsy, and evidence of polyneuropathy ( muscle weakness, altered sensation, autonomic symptoms). Central nervous System examination
On examination there will be seizures, cerebral ataxia, features of meningits (headache, photophobia, neck stiffness), cranial nerve palsy, and evidence of polyneuropathy ( muscle weakness, altered sensation, autonomic symptoms).
Mental State Examination This will reveals the presence of visual hallucinations, organic psychosis. Mental State Examination
This will reveals the presence of visual hallucinations, organic psychosis.
Examination of the eye General examination of the eye will reveals orbital infections like episcleritis, conjunctivitis and dry mucous membranes (in presence of Sjögren’s syndrome).
Visual acuity, colour vision and visual field will be affected in presence of optic neuritis.
Fundoscopic examination will reveals retinal infarctions with hard exudates and retinal haemorrhages.
Examination of the eye
General examination of the eye will reveals orbital infections like episcleritis, conjunctivitis and dry mucous membranes (in presence of Sjögren’s syndrome).
Visual acuity, colour vision and visual field will be affected in presence of optic neuritis.
Fundoscopic examination will reveals retinal infarctions with hard exudates and retinal haemorrhages.
abdominal examination General examination will reveals oral ulcers, icterus
In abdominal examination, mesenteric ischemia will reveals abdominal tenderness, gueding, rigidity will present in peritonitis, hypotension, tachicardia, tachypnoea will present in septicaemia, In liver failure there will be ankle oedema, ascitis.
abdominal examination
General examination will reveals oral ulcers, icterus
In abdominal examination, mesenteric ischemia will reveals abdominal tenderness, gueding, rigidity will present in peritonitis, hypotension, tachicardia, tachypnoea will present in septicaemia, In liver failure there will be ankle oedema, ascitis.
Cardiovascular examination In pericarditis with pericardial effusion will associated with pericardial rub.
in myocarditis patient will hve arrhythmias( irregular pulse, tacycardia), valve lesions with cardiomyopathy will have murmurs.
Cardiovascular examination
In pericarditis with pericardial effusion will associated with pericardial rub.
in myocarditis patient will hve arrhythmias( irregular pulse, tacycardia), valve lesions with cardiomyopathy will have murmurs.
evidence of neutropenia, lymphopenia, thrombocytopenia and haemolytic anaemia evidence of recurrent infection, easy bruising, pallor will present. evidence of neutropenia, lymphopenia, thrombocytopenia and haemolytic anaemia
evidence of recurrent infection, easy bruising, pallor will present.
Neonatal examination of a baby born to a mother with Systemic Lupus Erythematosus In here neonate will develop a skin rash, icterus following hepatitis and arrhythmias, syncopial attacks following heart block. Neonatal examination of a baby born to a mother with Systemic Lupus Erythematosus
In here neonate will develop a skin rash, icterus following hepatitis and arrhythmias, syncopial attacks following heart block.

Investigations - Diagnosis

Fact Explanation
full blood count patients can develop neutropenia, lymphopenia, thrombocytopenia and anaemia (Anaemia of
chronic disease or autoimmune haemolytic anaemia)
full blood count
patients can develop neutropenia, lymphopenia, thrombocytopenia and anaemia (Anaemia of
chronic disease or autoimmune haemolytic anaemia)
ESR, CRP In a controlled disease ESR will be high but CRP will be normal. But if there is any active inflammatory condition is present, CRP will be high. ESR, CRP
In a controlled disease ESR will be high but CRP will be normal. But if there is any active inflammatory condition is present, CRP will be high.
Autoantibodies like ANA, anti-dsDNA, anti-Ro, anti-Sm and anti-La There are several antibodies present in Systemic Lupus Erythematosus. ANA are positive in more than 95% of patients. Autoantibodies like ANA, anti-dsDNA, anti-Ro, anti-Sm and anti-La
There are several antibodies present in Systemic Lupus Erythematosus. ANA are positive in more than 95% of patients.
Serum complement C3 and C4 levels These are normal during the remission but levels are low during flareups. Serum complement C3 and C4 levels
These are normal during the remission but levels are low during flareups.
Renal function tests like UFR, serum creatinine, blood ures These tests help in diagnosing the renal involvement. Renal function tests like UFR, serum creatinine, blood ures
These tests help in diagnosing the renal involvement.
Liver function tests like AST, ALT, serum billirubin, serum albumin level and Ultrasound scan of the abdomen Liver function tests helpful in diagnosing the liver involvement and Ultrasound scan of the abdomen will help to assess the presence of ascitis . Liver function tests like AST, ALT, serum billirubin, serum albumin level and Ultrasound scan of the abdomen
Liver function tests helpful in diagnosing the liver involvement and Ultrasound scan of the abdomen will help to assess the presence of ascitis .
ECG, Echocardiogram These will be helpful in diagnosing the cardiovascular complications like pericardial effusions, arrhythmias, and valvular abnormalities. ECG, Echocardiogram
These will be helpful in diagnosing the cardiovascular complications like pericardial effusions, arrhythmias, and valvular abnormalities.
Chest X ray As Systemic Lupus Erythematosus can cause pulmonary involvement, Chest X ray is useful. Chest X ray
As Systemic Lupus Erythematosus can cause pulmonary involvement, Chest X ray is useful.
CT/ MRI scan of brain These tests will be useful in assessing cerebral complications. Brain arophy, brain infarction following vasculitis can be identified. CT/ MRI scan of brain
These tests will be useful in assessing cerebral complications. Brain arophy, brain infarction following vasculitis can be identified.
pleural aspirates for cytology, culture and ABST In the presence of pleural effusion these tests useful in identifyint the exudate anfd excluding pulmonary infections. pleural aspirates for cytology, culture and ABST
In the presence of pleural effusion these tests useful in identifyint the exudate anfd excluding pulmonary infections.
Histological and immunofluorescent study of biopsies from the kidney and the skin In these studies deposition of IgG and
complement will be identified. This will be useful in classifying the lupus nephritis as well.
Histological and immunofluorescent study of biopsies from the kidney and the skin
In these studies deposition of IgG and
complement will be identified. This will be useful in classifying the lupus nephritis as well.
CSF studies like CSF full report, culture and ABST These will be helpful in excluding the septic meningitis in patients with clinical symptoms and signd suggestive of meningitis. CSF studies like CSF full report, culture and ABST
These will be helpful in excluding the septic meningitis in patients with clinical symptoms and signd suggestive of meningitis.

Investigations - Management

Fact Explanation
FBC, blood picture and reticulocyte count patients can develop neutropenia, lymphopenia, thrombocytopenia and anaemia (Anaemia of
chronic disease or autoimmune haemolytic anaemia). blood picture will show normocytic normochromic anaemia with low counts of WBC and platelets. Reticulocyte count will be high
FBC, blood picture and reticulocyte count
patients can develop neutropenia, lymphopenia, thrombocytopenia and anaemia (Anaemia of
chronic disease or autoimmune haemolytic anaemia). blood picture will show normocytic normochromic anaemia with low counts of WBC and platelets. Reticulocyte count will be high
ESR, CRP In a controlled disease ESR will be high but CRP will be normal. But if there is any active inflammatory condition is present, CRP will be high. ESR, CRP
In a controlled disease ESR will be high but CRP will be normal. But if there is any active inflammatory condition is present, CRP will be high.
Serum complement C3 and C4 levels These are normal during the remission but levels are low during flareups. Serum complement C3 and C4 levels
These are normal during the remission but levels are low during flareups.
Histological and immunofluorescent study of biopsies from the kidney and the skin In these studies deposition of IgG and
complement will be identified. This will be useful in classifying the lupus nephritis as well.
Histological and immunofluorescent study of biopsies from the kidney and the skin
In these studies deposition of IgG and
complement will be identified. This will be useful in classifying the lupus nephritis as well.
Muscle biopsy There will be necrosis and inflammation on muscle biopsy in the presence of myositis. Muscle biopsy
There will be necrosis and inflammation on muscle biopsy in the presence of myositis.
Trans vaginal scan These patient are at risk of having recurrent miscarriages. So TVS will be helpful in assessing the patients condition. Trans vaginal scan
These patient are at risk of having recurrent miscarriages. So TVS will be helpful in assessing the patients condition.
Antiphospholipid antibodies This will give an idea about the prognosis of the patient as 25-40% of patients with positive Antiphospholipid antibodies will develop Antiphospholipid syndrome in future. Antiphospholipid antibodies
This will give an idea about the prognosis of the patient as 25-40% of patients with positive Antiphospholipid antibodies will develop Antiphospholipid syndrome in future.
Neonates investigate for neonatal lupus syndrome, Investigations like,
Ultrasound scan of the abdomen and liver function tests like AST,ALT, Serum bilirubin to look for any evidence of hepatitis.
ECG, Echocardiogram to look for the presence of heart block.
Neonates investigate for neonatal lupus syndrome,
Investigations like,
Ultrasound scan of the abdomen and liver function tests like AST,ALT, Serum bilirubin to look for any evidence of hepatitis.
ECG, Echocardiogram to look for the presence of heart block.
FBC This will be useful in looking for platelet count, haemoglobin level and WBC count when preparing the patient for invasive procedures. FBC
This will be useful in looking for platelet count, haemoglobin level and WBC count when preparing the patient for invasive procedures.
Clotting profile test with PT/INR, APTT Thesetest also useful to assess theclooting atatus of the patient. Clotting profile test with PT/INR, APTT
Thesetest also useful to assess theclooting atatus of the patient.
Renal function tests like UFR, serum creatinine, blood urea, Assessment of the renal function of the patient is useful during imaging and invasive procedures. Renal function tests like UFR, serum creatinine, blood urea,
Assessment of the renal function of the patient is useful during imaging and invasive procedures.
Liver function tests like AST, ALT, serum billirubin, serum albumin level and Ultrasound scan of the abdomen Liver function tests helpful in managemet to diagnosing the liver involvement . Liver function tests like AST, ALT, serum billirubin, serum albumin level and Ultrasound scan of the abdomen
Liver function tests helpful in managemet to diagnosing the liver involvement .
ECG, Echocardiogram These will be helpful in diagnosing the cardiovascular complications during themanagement. ECG, Echocardiogram
These will be helpful in diagnosing the cardiovascular complications during themanagement.
Chest X ray Chest X ray is also useful in assessing the fitness of the patient. Chest X ray
Chest X ray is also useful in assessing the fitness of the patient.
American Rheumatism Association Criteria for Systemic Lupus Erythematosus diagnosis (four or more of these features need to be present serially or simultaneously, on two separate occasions) Malar rash- Fixed erythema, flat or raised, sparing the nasolabial folds

Discoid rash- Erythematous raised patches with adherent keratotic scarring and follicular plugging

Photosensitivity- Rash as a result of unusual reaction to sunlight

Oral ulcers- Oral or nasopharyngeal ulceration, which may be painless

Arthritis- Non-erosive, involving two or more peripheral joints

Serositis- Pleuritis (convincing history of pleuritic pain or rub, or pleural effusion) or Pericarditis (rub, ECG evidence oreffusion)

Renal disorder- Persistent proteinuria > 0.5 g/day or Cellular casts (red cell, granular or tubular)

Neurological disorder- Seizures or psychosis, in the absence of offending drugs or metabolic derangement

Haematological disorder- Haemolytic anaemia or
Leucopenia2 (< 4 ××109/l), or
Lymphopenia2 (< 1 ××109/l), or
Thrombocytopenia2 (< 100 ××109/l) in the absence of offending drugs

Immunological disorder- Anti-DNA antibodies in abnormal titre or
Presence of antibody to Sm antigen or
Positive antiphospholipid antibodies

Antinuclear antibody (ANA) disorder- Abnormal titre of ANA by immunofluorescence
American Rheumatism Association Criteria for Systemic Lupus Erythematosus diagnosis (four or more of these features need to be present serially or simultaneously, on two separate occasions)
Malar rash- Fixed erythema, flat or raised, sparing the nasolabial folds

Discoid rash- Erythematous raised patches with adherent keratotic scarring and follicular plugging

Photosensitivity- Rash as a result of unusual reaction to sunlight

Oral ulcers- Oral or nasopharyngeal ulceration, which may be painless

Arthritis- Non-erosive, involving two or more peripheral joints

Serositis- Pleuritis (convincing history of pleuritic pain or rub, or pleural effusion) or Pericarditis (rub, ECG evidence oreffusion)

Renal disorder- Persistent proteinuria > 0.5 g/day or Cellular casts (red cell, granular or tubular)

Neurological disorder- Seizures or psychosis, in the absence of offending drugs or metabolic derangement

Haematological disorder- Haemolytic anaemia or
Leucopenia2 (< 4 ××109/l), or
Lymphopenia2 (< 1 ××109/l), or
Thrombocytopenia2 (< 100 ××109/l) in the absence of offending drugs

Immunological disorder- Anti-DNA antibodies in abnormal titre or
Presence of antibody to Sm antigen or
Positive antiphospholipid antibodies

Antinuclear antibody (ANA) disorder- Abnormal titre of ANA by immunofluorescence
Classification of Lupus Nephritis by international Society Of Nephrology and Renal pathology Society Class I – Minimal mesangial lupus nephritis:
with immune deposits but normal on light microscopy. Asymptomatic.

Class II – Mesangial proliferative lupus nephritis:
with mesangial hypercellularity and matrix expansion. Clinically, mild
renal disease.

Class III – Focal lupus nephritis:
(involving < 50% of glomeruli) with
subdivisions for active or chronic lesions. Subepithelial deposits seen. Clinically have haematuria and proteinuria.
10–20% of all lupus nephritis.

Class IV – Diffuse lupus nephritis:
(involving ≥ 50% of glomeruli) classified by the presence of segmental and global
lesions as well as active and chronic lesions.
Subendothelial deposits are present. Clinically there is progression to the nephrotic syndrome, hypertension and
renal insufficiency. Most common and most severe form
of lupus nephritis.

Class V – Membranous lupus nephritis: affects 10–20% of patients. Can occur in combination with III or IV. Good prognosis.

Class VI – Advanced sclerosing lupus nephritis:
(≥ 90% globally
sclerosed glomeruli without residual activity). This
represents the advanced stages of the above, as well as healing. Immunosuppressive therapy is unlikely to help as it is ‘inactive’. Progressive renal failure.
Classification of Lupus Nephritis by international Society Of Nephrology and Renal pathology Society
Class I – Minimal mesangial lupus nephritis:
with immune deposits but normal on light microscopy. Asymptomatic.

Class II – Mesangial proliferative lupus nephritis:
with mesangial hypercellularity and matrix expansion. Clinically, mild
renal disease.

Class III – Focal lupus nephritis:
(involving < 50% of glomeruli) with
subdivisions for active or chronic lesions. Subepithelial deposits seen. Clinically have haematuria and proteinuria.
10–20% of all lupus nephritis.

Class IV – Diffuse lupus nephritis:
(involving ≥ 50% of glomeruli) classified by the presence of segmental and global
lesions as well as active and chronic lesions.
Subendothelial deposits are present. Clinically there is progression to the nephrotic syndrome, hypertension and
renal insufficiency. Most common and most severe form
of lupus nephritis.

Class V – Membranous lupus nephritis: affects 10–20% of patients. Can occur in combination with III or IV. Good prognosis.

Class VI – Advanced sclerosing lupus nephritis:
(≥ 90% globally
sclerosed glomeruli without residual activity). This
represents the advanced stages of the above, as well as healing. Immunosuppressive therapy is unlikely to help as it is ‘inactive’. Progressive renal failure.
Urine for protein and red blood cells As these patients are at risk of developing renal failure all patients are regularly screened and look for presence of protein and red blood cells in the urine. Fro these tests lupus nephritis can be diagnosed in early stages before going into renal impairment. Urine for protein and red blood cells
As these patients are at risk of developing renal failure all patients are regularly screened and look for presence of protein and red blood cells in the urine. Fro these tests lupus nephritis can be diagnosed in early stages before going into renal impairment.
Uterine artery doppler study This should be done at 24 weeks of pregnancy associated with systemic lupus erythematosus to screen the foetal growht and well being. Uterine artery doppler study
This should be done at 24 weeks of pregnancy associated with systemic lupus erythematosus to screen the foetal growht and well being.

Management - Supportive

Fact Explanation
Health education Patient should be educated regarding the disease, symptoms associated with, possible complications, investigations needed, available treatment options, predisposing factors for exacerbations and prognosis. As this is a life long genetically transmitting disease that fact also need to be address. Health education
Patient should be educated regarding the disease, symptoms associated with, possible complications, investigations needed, available treatment options, predisposing factors for exacerbations and prognosis. As this is a life long genetically transmitting disease that fact also need to be address.
Life style modification Due to the symptoms associated with the disease patient's normal day to day life can be affected.
eg: malaise, lethargy, fatiguability will limit the patient to bed.
Joint pain and deformities will interfere with fine works.
This should be discussed with the patient and physiotherapy, occupational therapy and help from social services can be afforded to improve the quality of life.
Life style modification
Due to the symptoms associated with the disease patient's normal day to day life can be affected.
eg: malaise, lethargy, fatiguability will limit the patient to bed.
Joint pain and deformities will interfere with fine works.
This should be discussed with the patient and physiotherapy, occupational therapy and help from social services can be afforded to improve the quality of life.
Avoid precipitating factors Patient should be provide informations regarding precipitating factors like excessive exposure to sun light, drugs causing exacerbations and hormone replacement therapy.
These factors should be avoided (eg: use high factor sun blocks to minimize UV light exposure) as much as possible and patient should be educated to early identification of exacerbations.
Avoid precipitating factors
Patient should be provide informations regarding precipitating factors like excessive exposure to sun light, drugs causing exacerbations and hormone replacement therapy.
These factors should be avoided (eg: use high factor sun blocks to minimize UV light exposure) as much as possible and patient should be educated to early identification of exacerbations.

Management - Specific

Fact Explanation
Multidisciplinary team management This is very important in managing patients with Systemic Lupus Erythematosus as it affect multi systems of the patients. This multidisciplinary team will need various specialist of the doctors according to the condition of the patient.
eg: Physician- In managing the general condition of the patient
Cardiologist/ cardiothoracic surgeon- in managing the cardiac complications like pericardial effusion, arrhythmias, valve problems
Neurologist- In managing the cerebral lupus
Rheumatologist- to manage arthritis and joint deformities
Dermatologist- in managing the skin conditions
Immunologist- In assessing the immunological status of the patient
Nephrologist- In the presence of lupus nephritis
Pulmonarologist- In presence of pulmonary complication
Haematologist- In managing haematological complications (neurtropenia, leucopenia, thrombocytopenia and anaemia) , Pathologist- In assessing the histology ogf the patient
Gynaecologist- in recurrent miscarriages
Radiologist- In investigating the patient
Gastroenterologist/ surgeon- in presence of gastrointestinal complication like mesenteric ischemia, bowel perforation
Psychiatrist- in psychological counseling

Other than doctors nursing care by nurses, physiotherapists, occupational therapists, social workers, relatives need to be included.
Genetic specialist in genetic counseling. 5]
Multidisciplinary team management
This is very important in managing patients with Systemic Lupus Erythematosus as it affect multi systems of the patients. This multidisciplinary team will need various specialist of the doctors according to the condition of the patient.
eg: Physician- In managing the general condition of the patient
Cardiologist/ cardiothoracic surgeon- in managing the cardiac complications like pericardial effusion, arrhythmias, valve problems
Neurologist- In managing the cerebral lupus
Rheumatologist- to manage arthritis and joint deformities
Dermatologist- in managing the skin conditions
Immunologist- In assessing the immunological status of the patient
Nephrologist- In the presence of lupus nephritis
Pulmonarologist- In presence of pulmonary complication
Haematologist- In managing haematological complications (neurtropenia, leucopenia, thrombocytopenia and anaemia) , Pathologist- In assessing the histology ogf the patient
Gynaecologist- in recurrent miscarriages
Radiologist- In investigating the patient
Gastroenterologist/ surgeon- in presence of gastrointestinal complication like mesenteric ischemia, bowel perforation
Psychiatrist- in psychological counseling

Other than doctors nursing care by nurses, physiotherapists, occupational therapists, social workers, relatives need to be included.
Genetic specialist in genetic counseling. 5]
Non Steroid Anti Inflammatory Drugs In the presence of arthralgia, arthritis, serositis, fever and other constitutional symptoms standard doses of Non Steroid Anti Inflammatory Drugs will be useful. Non Steroid Anti Inflammatory Drugs
In the presence of arthralgia, arthritis, serositis, fever and other constitutional symptoms standard doses of Non Steroid Anti Inflammatory Drugs will be useful.
Topical corticosteroids Topical corticosteroids are helpful in managing the skin conditions in cutaneous lupus. Topical corticosteroids
Topical corticosteroids are helpful in managing the skin conditions in cutaneous lupus.
Antimalarial drugs Antimalarial drugs like chloroquine, hydroxychloroquine can be used in mild skin disease, fatigue
and arthralgias where those symptoms cannot be controlled with NSAIDs
Antimalarial drugs
Antimalarial drugs like chloroquine, hydroxychloroquine can be used in mild skin disease, fatigue
and arthralgias where those symptoms cannot be controlled with NSAIDs
Corticosteroids Various types of corticosteroids can be use to treat this condition.
eg:
Short course of oral corticosteroids in mild to moderate disease condition like presence of rash, serositis.

Single intramuscular injections of long-acting corticosteroids or short courses of oral corticosteroids are useful in treating
severe flares of arthritis, pleuritis or pericarditis.

High dose of oral corticosteroids in lupus nephritis, cerebral lupus, severe haemolytic
anaemia or thrombocytopenia.
Corticosteroids
Various types of corticosteroids can be use to treat this condition.
eg:
Short course of oral corticosteroids in mild to moderate disease condition like presence of rash, serositis.

Single intramuscular injections of long-acting corticosteroids or short courses of oral corticosteroids are useful in treating
severe flares of arthritis, pleuritis or pericarditis.

High dose of oral corticosteroids in lupus nephritis, cerebral lupus, severe haemolytic
anaemia or thrombocytopenia.
immunosuppressive drugs in addition to high dose of oral corticosteroids in lupus nephritis and cerebral lupus patients should be treated with immunosuppressive drugs like Cyclophosphamide, mycophenolate
mofetil.
Azathioprine like immunosuppressive drugs are used in maintaining remissions.
immunosuppressive drugs
in addition to high dose of oral corticosteroids in lupus nephritis and cerebral lupus patients should be treated with immunosuppressive drugs like Cyclophosphamide, mycophenolate
mofetil.
Azathioprine like immunosuppressive drugs are used in maintaining remissions.
Newer drugs like rituximab These are used in refractory cases of Systemic Lupus Erythematosus. It reduces the auto antibody levels by suppressing levels of CD20 positive B lymphocytes. Newer drugs like rituximab
These are used in refractory cases of Systemic Lupus Erythematosus. It reduces the auto antibody levels by suppressing levels of CD20 positive B lymphocytes.
warfarin Patients with past history of previous thrombotic complications should be given life-long warfarin. warfarin
Patients with past history of previous thrombotic complications should be given life-long warfarin.
Management of pregnancy In Systemic Lupus Erythematosus As mentioned above multidisciplinary team management should be considered.

Pre- pregnant counseling about maternal risks (eg; increased risk of flareup, risk of development of hypertension, pre-eclampsia, placental abruption)
and foetal risk (eg: pre term deliverty, pre term rupture of membranes, intra uterine growth retardation, intra uterine foetal death and development of neonatal lpus syndrome).

advice to conceive during remissions as there is less risk of flare up.

Treat hypertension and closely monitor for the foetures of pre eclampsis and imminent eclampsia.

Treat flare ups similer to non pregnant state. advice patients not to stop hydroxychloroquine if patient is already on, as it can precipitate flare up.

Manage the pregnancy in a hospital with tertiary care facilities available.

closely monitor maternal and foetal well being.
Management of pregnancy In Systemic Lupus Erythematosus
As mentioned above multidisciplinary team management should be considered.

Pre- pregnant counseling about maternal risks (eg; increased risk of flareup, risk of development of hypertension, pre-eclampsia, placental abruption)
and foetal risk (eg: pre term deliverty, pre term rupture of membranes, intra uterine growth retardation, intra uterine foetal death and development of neonatal lpus syndrome).

advice to conceive during remissions as there is less risk of flare up.

Treat hypertension and closely monitor for the foetures of pre eclampsis and imminent eclampsia.

Treat flare ups similer to non pregnant state. advice patients not to stop hydroxychloroquine if patient is already on, as it can precipitate flare up.

Manage the pregnancy in a hospital with tertiary care facilities available.

closely monitor maternal and foetal well being.

Concise, fact-based medical articles to refresh your knowledge

Access a wealth of content and skim through a smartly presented catalog of diseases and conditions.

  1. ADAMS WALDORF KM, NELSON JL. AUTOIMMUNE DISEASE DURING PREGNANCY AND THE MICROCHIMERISM LEGACY OF PREGNANCY Immunol Invest [online] 2008, 37(5):631-644 [viewed 16 October 2014] Available from: doi:10.1080/08820130802205886
  2. AL-AMRY M. Nodular episcleritis after laser in situ keratomileusis in patient with systemic lupus erythematosus Oman J Ophthalmol [online] 2013, 6(1):65-66 [viewed 17 October 2014] Available from: doi:10.4103/0974-620X.111938
  3. ANDERS HJ, WEENING JJ. Kidney disease in lupus is not always 'lupus nephritis' Arthritis Res Ther [online] 2013, 15(2):108 [viewed 17 October 2014] Available from: doi:10.1186/ar4166
  4. APPLEBY P, WEBBER DG, BOWEN JG. Murine chronic graft-versus-host disease as a model of systemic lupus erythematosus: effect of immunosuppressive drugs on disease development. Clin Exp Immunol [online] 1989 Dec, 78(3):449-453 [viewed 17 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1534813
  5. ASHERSON RA, CHAN JK, HARRIS EN, GHARAVI AE, HUGHES GR. Anticardiolipin antibody, recurrent thrombosis, and warfarin withdrawal. Ann Rheum Dis [online] 1985 Dec, 44(12):823-825 [viewed 17 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1001791
  6. BAGAVANT H, FU SM. Pathogenesis of kidney disease in systemic lupus erythematosus Curr Opin Rheumatol [online] 2009 Sep, 21(5):489-494 [viewed 16 October 2014] Available from: doi:10.1097/BOR.0b013e32832efff1
  7. BARBER KA, JACKSON R. Neonatal lupus erythematosus: five new cases with HLA typing. Can Med Assoc J [online] 1983 Jul 15, 129(2):139-141 [viewed 17 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1875279
  8. BASHAL F. Hematological Disorders in Patients with Systemic Lupus Erythematosus Open Rheumatol J [online] :87-95 [viewed 16 October 2014] Available from: doi:10.2174/1874312901307010087
  9. BENARROCH-GAMPEL J, SHEFFIELD KM, DUNCAN CB, BROWN KM, HAN Y, TOWNSEND CM JR, RIALL TS. Preoperative Laboratory Testing in Patients Undergoing Elective, Low-Risk Ambulatory Surgery Ann Surg [online] 2012 Sep, 256(3):518-528 [viewed 20 October 2014] Available from: doi:10.1097/SLA.0b013e318265bcdb
  10. BERLIT P. Diagnosis and treatment of cerebral vasculitis Ther Adv Neurol Disord [online] 2010 Jan, 3(1):29-42 [viewed 16 October 2014] Available from: doi:10.1177/1756285609347123
  11. BERTOUCH JV, ROBERTS-THOMPSON PJ, FENG PH, BRADLEY J. C-reactive protein and serological indices of disease activity in systemic lupus erythematosus. Ann Rheum Dis [online] 1983 Dec, 42(6):655-658 [viewed 16 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1001323
  12. BOEHME MW, RAETH U, GALLE PR, STREMMEL W, SCHERBAUM WA. Serum thrombomodulin--a reliable marker of disease activity in systemic lupus erythematosus (SLE): advantage over established serological parameters to indicate disease activity Clin Exp Immunol [online] 2000 Jan, 119(1):189-195 [viewed 16 October 2014] Available from: doi:10.1046/j.1365-2249.2000.01107.x
  13. BONILLA-ABADíA F, CORONEL RESTREPO N, TOBóN GJ, ECHEVERRI AF, MUñOZ-BUITRóN E, CASTRO AM, BEJARANO MA, CAñAS CA. Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus Autoimmune Dis [online] 2014:731806 [viewed 17 October 2014] Available from: doi:10.1155/2014/731806
  14. BONTEMPO FA, LEWIS JH, VAN THIEL DH, SPERO JA, RAGNI MV, BUTLER P, ISRAEL L, STARZL TE. THE RELATION OF PREOPERATIVE COAGULATION FINDINGS TO DIAGNOSIS, BLOOD USAGE, AND SURVIVAL IN ADULT LIVER TRANSPLANTATION Transplantation [online] 1985 May, 39(5):532-536 [viewed 20 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988424
  15. BRESNIHAN B, OLIVER M, GRIGOR R, HUGHES GR. Brain reactivity of lymphocytotoxic antibodies in systemic lupus erythematosus with and without cerebral involvement. Clin Exp Immunol [online] 1977 Dec, 30(3):333-337 [viewed 16 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1541136
  16. CACCAVO D, DEL PORTO F, GARZIA P, MITTERHOFER A, GALLUZZO S, RIGON A, VADACCA M, NAVAJAS M, AMOROSO A, AFELTRA A. Raynaud's phenomenon and antiphospholipid antibodies in systemic lupus erythematosus: is there an association? Ann Rheum Dis [online] 2003 Oct, 62(10):1003-1005 [viewed 16 October 2014] Available from: doi:10.1136/ard.62.10.1003
  17. CAMERON JS, LESSOF MH, OGG CS, WILLIAMS BD, WILLIAMS DG. Disease activity in the nephritis of systemic lupus erythematosus in relation to serum complement concentrations. DNA-binding capacity and precipitating anti-DNA antibody. Clin Exp Immunol [online] 1976 Sep, 25(3):418-427 [viewed 17 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1541413
  18. CHARLESWORTH JA, PEAKE PW, GOLDING J, MACKIE JD, PUSSELL BA, TIMMERMANS V, WAKEFIELD D. Hypercatabolism of C3 and C4 in active and inactive systemic lupus erythematosus. Ann Rheum Dis [online] 1989 Feb, 48(2):153-159 [viewed 16 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1003704
  19. CLINICAL VIGNETTES J Gen Intern Med [online] 2004 Apr, 19(Suppl 1):23-83 [viewed 16 October 2014] Available from: doi:10.1111/j.1525-1497.2004.S1006_1.x
  20. COJOCARU M, COJOCARU IM, SILOSI I, VRABIE CD. Gastrointestinal Manifestations in Systemic Autoimmune Diseases Maedica (Buchar) [online] 2011 Jan, 6(1):45-51 [viewed 16 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150032
  21. COJOCARU M, COJOCARU IM, SILOSI I, VRABIE CD. Manifestations of Systemic Lupus Erythematosus Maedica (Buchar) [online] 2011 Oct, 6(4):330-336 [viewed 16 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3391953
  22. D'CRUZ DP, KESER G, DIRESKENELI H, KHAMASHTA MA, HUGHES GR. Anti-endothelial cell antibodies in systemic vasculitis and systemic lupus erythematosus (SLE): effects of heat inactivation on binding and specificity Clin Exp Immunol [online] 1999 Mar, 115(3):567-570 [viewed 16 October 2014] Available from: doi:10.1046/j.1365-2249.1999.00845.x
  23. DE JONGSTE JC, NEIJENS HJ, DUIVERMAN EJ, BOGAARD JM, KERREBIJN KF. Respiratory tract disease in systemic lupus erythematosus. Arch Dis Child [online] 1986 May, 61(5):478-483 [viewed 16 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1777806
  24. DRABORG AH, DUUS K, HOUEN G. Epstein-Barr Virus in Systemic Autoimmune Diseases Clin Dev Immunol [online] 2013:535738 [viewed 16 October 2014] Available from: doi:10.1155/2013/535738
  25. ECKSTEIN MB, SPALTON DJ, HOLDER G. Visual loss from central serous retinopathy in systemic lupus erythematosus. Br J Ophthalmol [online] 1993 Sep, 77(9):607-609 [viewed 16 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC513966
  26. ELKAYAM U, WEISS S, LANIADO S. Pericardial effusion and mitral valve involvement in systemic lupus erythematosus. Echocardiographic study. Ann Rheum Dis [online] 1977 Aug, 36(4):349-353 [viewed 16 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1006696
  27. ERGIN RN. Pregnancy-associated systemic lupus erythematosus Proc (Bayl Univ Med Cent) [online] 2014 Jul, 27(3):221-222 [viewed 18 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059571
  28. EROGLU G, KOHLER P. Familial systemic lupus erythematosus: the role of genetic and environmental factors Ann Rheum Dis [online] 2002 Jan, 61(1):29-31 [viewed 16 October 2014] Available from: doi:10.1136/ard.61.1.29
  29. FARIA DA, REVOREDO LS, VILAR MJ, EULáLIA MARIA CHAVES M. Resilience and Treatment Adhesion in Patients with Systemic Lupus Erythematosus Open Rheumatol J [online] :1-8 [viewed 17 October 2014] Available from: doi:10.2174/1874312920140127001
  30. FISHBEIN E, ALARCON-SEGOVIA D, VEGA JM. Antibodies to histones in systemic lupus erythematosus. Clin Exp Immunol [online] 1979 Apr, 36(1):145-150 [viewed 16 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1537691
  31. FONT J, CERVERA R, INGELMO M, TORRAS A, DARNELL A, REVERT L. Systemic lupus erythematosus without clinical renal abnormalities. Ann Rheum Dis [online] 1986 Mar, 45(3):260-261 [viewed 16 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1001862
  32. FORD HB, SCHUST DJ. Recurrent Pregnancy Loss: Etiology, Diagnosis, and Therapy Rev Obstet Gynecol [online] 2009, 2(2):76-83 [viewed 17 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2709325
  33. FRITZLER MJ, TAN EM. Antibodies to Histones in Drug-Induced and Idiopathic Lupus Erythematosus J Clin Invest [online] 1978 Sep, 62(3):560-567 [viewed 16 October 2014] Available from: doi:10.1172/JCI109161
  34. FUKUDA T, BRUNNER HI, SAGCAL-GIRONELLA AC, VINKS AA. Non-steroidal Anti-Inflammatory Drugs may reduce Enterohepatic Recirculation of Mycophenolic Acid in Patients with Childhood-onset Systemic Lupus Erythematosus Ther Drug Monit [online] 2011 Oct, 33(5):658-662 [viewed 17 October 2014] Available from: doi:10.1097/FTD.0b013e318228195f
  35. GAN L, O’HANLON TP, GORDON AS, RIDER LG, MILLER FW, BURBELO PD. Twins discordant for myositis and systemic lupus erythematosus show markedly enriched autoantibodies in the affected twin supporting environmental influences in pathogenesis BMC Musculoskelet Disord [online] :67 [viewed 16 October 2014] Available from: doi:10.1186/1471-2474-15-67
  36. GHIRARDELLO A, DORIA A, RUFFATTI A, RIGOLI AM, VESCO P, CALLIGARO A, GAMBARI PF. Antiphospholipid antibodies (aPL) in systemic lupus erythematosus. Are they specific tools for the diagnosis of aPL syndrome? Ann Rheum Dis [online] 1994 Feb, 53(2):140-142 [viewed 17 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1005268
  37. GORDON KA, TOSTI A. Alopecia: evaluation and treatment Clin Cosmet Investig Dermatol [online] :101-106 [viewed 16 October 2014] Available from: doi:10.2147/CCID.S10182
  38. GORDON M, PORTER D, CAPELL H. Does sulphasalazine cause drug induced systemic lupus erythematosus? No effect evident in a prospective randomised trial of 200 rheumatoid patients treated with sulphasalazine or auranofin over five years Ann Rheum Dis [online] 1999 May, 58(5):288-290 [viewed 16 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1752876
  39. HOPKINSON N. Epidemiology of systemic lupus erythematosus. Ann Rheum Dis [online] 1992 Dec, 51(12):1292-1294 [viewed 16 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC100492
  40. HOPKINSON NP, LIM K, GARDNER-MEDWIN J. Antiphospholipid antibodies (aPL) in systemic lupus erythematosus. Are they specific tools for the diagnosis of aPL syndrome? Ann Rheum Dis [online] 1994 Sep, 53(9):619-620 [viewed 17 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1005420
  41. ISENBERG DA, MORROW WJ, SNAITH ML. Methyl prednisolone pulse therapy in the treatment of systemic lupus erythematosus. Ann Rheum Dis [online] 1982 Aug, 41(4):347-351 [viewed 17 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1000949
  42. JAMES JA, ROBERTSON JM. Lupus and Epstein-Barr Curr Opin Rheumatol [online] 2012 Jul, 24(4):383-388 [viewed 16 October 2014] Available from: doi:10.1097/BOR.0b013e3283535801
  43. JIA Y, ORTIZ A, MCCALLUM R, SALAMEH H, SERRATO P. Acute Pancreatitis as the Initial Presentation of Systematic Lupus Erythematosus Case Rep Gastrointest Med [online] 2014:571493 [viewed 16 October 2014] Available from: doi:10.1155/2014/571493
  44. JONES HW, IRELAND R, SENALDI G, WANG F, KHAMASHTA M, BELLINGHAM AJ, VEERAPAN K, HUGHES GR, VERGANI D. Anticardiolipin antibodies in patients from Malaysia with systemic lupus erythematosus. Ann Rheum Dis [online] 1991 Mar, 50(3):173-175 [viewed 17 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1004368
  45. KALIńSKA-BIENIAS A, KOWALEWSKI C, WOźNIAK K. Terbinafine-induced subacute cutaneous lupus erythematosus in two patients with systemic lupus erythematosus successfully treated with topical corticosteroids Postepy Dermatol Alergol [online] 2013 Aug, 30(4):261-264 [viewed 17 October 2014] Available from: doi:10.5114/pdia.2013.37038
  46. KEANE M, LYNCH J. Pleuropulmonary manifestations of systemic lupus erythematosus Thorax [online] 2000 Feb, 55(2):159-166 [viewed 16 October 2014] Available from: doi:10.1136/thorax.55.2.159
  47. KLEIN RS, SAYRE RM, DOWDY JC, WERTH VP. The risk of ultraviolet radiation exposure from indoor lamps in lupus erythematosus Autoimmun Rev [online] 2009 Feb, 8(4):320-324 [viewed 16 October 2014] Available from: doi:10.1016/j.autrev.2008.10.003
  48. KOLE AK, GHOSH A. CUTANEOUS MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS IN A TERTIARY REFERRAL CENTER Indian J Dermatol [online] 2009, 54(2):132-136 [viewed 16 October 2014] Available from: doi:10.4103/0019-5154.53189
  49. KUECHLE MK, ELKON KB. Shining light on lupus and UV Arthritis Res Ther [online] 2007, 9(1):101 [viewed 16 October 2014] Available from: doi:10.1186/ar2100
  50. LANDRY M, SAMS WM JR. Systemic Lupus Erythematosus. STUDIES OF THE ANTIBODIES BOUND TO SKIN J Clin Invest [online] 1973 Aug, 52(8):1871-1880 [viewed 16 October 2014] Available from: doi:10.1172/JCI107370
  51. LAWSON EF, YAZDANY J. Healthcare quality in systemic lupus erythematosus: using Donabedian's conceptual framework to understand what we know Int J Clin Rheumtol [online] 2012 Feb, 7(1):95-107 [viewed 17 October 2014] Available from: doi:10.2217/ijr.11.65
  52. LEVY DM, KAMPHUIS S. Systemic Lupus Erythematosus in Children and Adolescents Pediatr Clin North Am [online] 2012 Apr, 59(2):345-364 [viewed 16 October 2014] Available from: doi:10.1016/j.pcl.2012.03.007
  53. MAIDHOF W, HILAS O. Lupus: An Overview of the Disease And Management Options P T [online] 2012 Apr, 37(4):240-249 [viewed 16 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351863
  54. MANDAL M, TRIPATHY R, PANDA AK, PATTANAIK SS, DAKUA S, PRADHAN AK, CHAKRABORTY S, RAVINDRAN B, DAS BK. Vitamin D levels in Indian systemic lupus erythematosus patients: association with disease activity index and interferon alpha Arthritis Res Ther [online] 2014, 16(1):R49 [viewed 17 October 2014] Available from: doi:10.1186/ar4479
  55. MAXWELL CJ, POTTER E, TOWNSEND J. Severe Raynaud's Phenomenon in a Patient With Antinuclear Antibody-Negative Systemic Lupus Erythematosus J Natl Med Assoc [online] 1988 May, 80(5):594-595 [viewed 16 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2625762
  56. MOK C, WONG R. Pregnancy in systemic lupus erythematosus Postgrad Med J [online] 2001 Mar, 77(905):157-165 [viewed 17 October 2014] Available from: doi:10.1136/pmj.77.905.157
  57. MOK CC, LAU CS. Pathogenesis of systemic lupus erythematosus J Clin Pathol [online] 2003 Jul, 56(7):481-490 [viewed 16 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1769989
  58. MORAND EF, MCCLOUD PI, LITTLEJOHN GO. Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis [online] 1992 Dec, 51(12):1318-1321 [viewed 17 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1004927
  59. MUBARAK M, NASRI H. ISN/RPS 2003 classification of lupus nephritis: time to take a look on the achievements and limitations of the schema J Nephropathol [online] 2014 Jul, 3(3):87-90 [viewed 17 October 2014] Available from: doi:10.12860/jnp.2014.17
  60. MUSCAL E, BREY RL. Neurological Manifestations of Systemic Lupus Erythematosus in Children and Adults Neurol Clin [online] 2010 Feb, 28(1):61-73 [viewed 16 October 2014] Available from: doi:10.1016/j.ncl.2009.09.004
  61. NAYAK RB, BHOGALE GS, PATIL NM, CHATE SS. Psychosis in Patients with Systemic Lupus Erythematosus Indian J Psychol Med [online] 2012, 34(1):90-93 [viewed 16 October 2014] Available from: doi:10.4103/0253-7176.96170
  62. PARONETTO F, KOFFLER D. Immunofluorescent localization of immunoglobulins, complement, and fibrinogen in human diseases. I. Systemic lupus erythematosus. J Clin Invest [online] 1965 Oct, 44(10):1657-1664 [viewed 16 October 2014] Available from: doi:10.1172/JCI105272
  63. PATEL RM, MARFATIA YS. LUPUS PANNICULITIS AS AN INITIAL MANIFESTATION OF SYSTEMIC LUPUS ERYTHEMATOSUS Indian J Dermatol [online] 2010, 55(1):99-101 [viewed 16 October 2014] Available from: doi:10.4103/0019-5154.60364
  64. PATERSON A, TIMPERLEY W, SLATER D. Coagulation abnormalities in fatal cerebral lupus erythematosus. J R Soc Med [online] 1981 Jan, 74(1):53-55 [viewed 16 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1438326
  65. PIETTE JC, FRANCES C, PAPO T, KARMOCHKINE M. Vasculopathy and antiphospholipid antibodies in systemic lupus. J Clin Pathol [online] 1993 Aug, 46(8):781-782 [viewed 17 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC501477
  66. PONTICELLI C, IMBASCIATI E, BRANCACCIO D, TARANTINO A, RIVOLTA E. Acute Renal Failure in Systemic Lupus Erythematosus Br Med J [online] 1974 Sep 21, 3(5933):716-719 [viewed 16 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1611813
  67. RAMOS PS, BROWN EE, KIMBERLY RP, LANGEFELD CD. Genetic Factors Predisposing to Systemic Lupus Erythematosus and Lupus Nephritis Semin Nephrol [online] 2010 Mar, 30(2):164-176 [viewed 16 October 2014] Available from: doi:10.1016/j.semnephrol.2010.01.007
  68. RHO YH, OESER A, CHUNG CP, MORROW JD, STEIN CM. Drugs to Treat Systemic Lupus Erythematosus: Relationship between Current Use and Cardiovascular Risk Factors Arch Drug Inf [online] 2008 Jul, 1(1):23-28 [viewed 17 October 2014] Available from: doi:10.1111/j.1753-5174.2007.00004.x
  69. SAMANTA A, FEEHALLY J, ROY S, NICHOL FE, SHELDON PJ, WALLS J. High prevalence of systemic disease and mortality in Asian subjects with systemic lupus erythematosus. Ann Rheum Dis [online] 1991 Jul, 50(7):490-492 [viewed 17 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1004464
  70. SCHMAJUK G, YAZDANY J, TRUPIN L, YELIN E. Hydroxychloroquine use in a community-based cohort of patients with systemic lupus erythematosus Arthritis Care Res (Hoboken) [online] 2010 Mar, 62(3):386-392 [viewed 17 October 2014] Available from: doi:10.1002/acr.20002
  71. SMYTH A, OLIVEIRA GH, LAHR BD, BAILEY KR, NORBY SM, GAROVIC VD. A Systematic Review and Meta-Analysis of Pregnancy Outcomes in Patients with Systemic Lupus Erythematosus and Lupus Nephritis Clin J Am Soc Nephrol [online] 2010 Nov, 5(11):2060-2068 [viewed 18 October 2014] Available from: doi:10.2215/CJN.00240110
  72. SOKOL RJ, BOOKER DJ, STAMPS R. The pathology of autoimmune haemolytic anaemia. J Clin Pathol [online] 1992 Dec, 45(12):1047-1052 [viewed 18 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC494994
  73. SWAAK AJ, NOSSENT JC, BRONSVELD W, VAN ROOYEN A, NIEUWENHUYS EJ, THEUNS L, SMEENK RJ. Systemic lupus erythematosus. II. Observations on the occurrence of exacerbations in the disease course: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis [online] 1989 Jun, 48(6):455-460 [viewed 17 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1003787
  74. TAKEUCHI T, AMANO K, SEKINE H, KOIDE J, ABE T. Upregulated expression and function of integrin adhesive receptors in systemic lupus erythematosus patients with vasculitis. J Clin Invest [online] 1993 Dec, 92(6):3008-3016 [viewed 16 October 2014] Available from: doi:10.1172/JCI116924
  75. THEODORIDOU A, SETTAS L. Demyelination in rheumatic diseases J Neurol Neurosurg Psychiatry [online] 2006 Mar, 77(3):290-295 [viewed 16 October 2014] Available from: doi:10.1136/jnnp.2005.075861
  76. TIAN XP, ZHANG X. Gastrointestinal involvement in systemic lupus erythematosus: Insight into pathogenesis, diagnosis and treatment World J Gastroenterol [online] 2010 Jun 28, 16(24):2971-2977 [viewed 16 October 2014] Available from: doi:10.3748/wjg.v16.i24.2971
  77. TONNER C, TRUPIN L, YAZDANY J, CRISWELL L, KATZ P, YELIN E. Role of Community and Individual Characteristics in Physician Visits for Persons With Systemic Lupus Erythematosus Arthritis Care Res (Hoboken) [online] 2010 Jun, 62(6):888-895 [viewed 17 October 2014] Available from: doi:10.1002/acr.20125
  78. TRACZEWSKI P, RUDNICKA L. Treatment of systemic lupus erythematosus with epratuzumab Br J Clin Pharmacol [online] 2011 Feb, 71(2):175-182 [viewed 17 October 2014] Available from: doi:10.1111/j.1365-2125.2010.03767.x
  79. TSOKOS GC. Drugs, sun and T cells in lupus Clin Exp Immunol [online] 2004 May, 136(2):191-193 [viewed 17 October 2014] Available from: doi:10.1111/j.1365-2249.2004.02455.x
  80. TSUKAMOTO H, UEDA A, NAGASAWA K, TADA Y, NIHO Y. Increased production of the third component of complement (C3) by monocytes from patients with systemic lupus erythematosus. Clin Exp Immunol [online] 1990 Nov, 82(2):257-261 [viewed 16 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1535108
  81. Treatment of Systemic Lupus Erythematosus with Steroids: Report to The Medical Research Council by The Collagen Diseases and Hypersensitivity Panel Br Med J [online] 1961 Oct 7, 2(5257):915-920 [viewed 17 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1969959
  82. VELTHUIS PJ, KATER L, VAN DER TWEEL I, DE LA FAILLE HB, VAN VLOTEN WA. Immunofluorescence microscopy of healthy skin from patients with systemic lupus erythematosus: more than just the lupus band. Ann Rheum Dis [online] 1992 Jun, 51(6):720-725 [viewed 17 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1004733
  83. VOULGARELIS M, KOKORI S, IOANNIDIS J, TZIOUFAS A, KYRIAKI D, MOUTSOPOULOS H. Anaemia in systemic lupus erythematosus: aetiological profile and the role of erythropoietin Ann Rheum Dis [online] 2000 Mar, 59(3):217-222 [viewed 16 October 2014] Available from: doi:10.1136/ard.59.3.217
  84. VYAS V, SHUKLA D, PATIL S, MOHITE S. Caesarean section in a case of systemic lupus erythematosus Indian J Anaesth [online] 2014, 58(2):193-195 [viewed 17 October 2014] Available from: doi:10.4103/0019-5049.130827
  85. WYSENBEEK AJ, GUEDJ D, AMIT M, WEINBERGER A. Rash in systemic lupus erythematosus: prevalence and relation to cutaneous and non-cutaneous disease manifestations. Ann Rheum Dis [online] 1992 Jun, 51(6):717-719 [viewed 16 October 2014] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1004732
  86. YUNG R, POWERS D, JOHNSON K, AMENTO E, CARR D, LAING T, YANG J, CHANG S, HEMATI N, RICHARDSON B. Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice. J Clin Invest [online] 1996 Jun 15, 97(12):2866-2871 [viewed 17 October 2014] Available from: doi:10.1172/JCI118743
  87. ZELLER CB, APPENZELLER S. Cardiovascular Disease in Systemic Lupus Erythematosus: The Role of Traditional and Lupus Related Risk Factors Curr Cardiol Rev [online] 2008 May, 4(2):116-122 [viewed 16 October 2014] Available from: doi:10.2174/157340308784245775